AstraZeneca to Acquire Genexine $AstraZeneca PLC(AZN)$ announced on Tuesday that it has formally reached an agreement to acquire Chinese company $Gracell Biotechnologies Inc.(GRCL)$ or up to $1.2 billion, as part of its efforts to expand its cell therapy business. The deal includes $1 billion in cash, as well as non-negotiable cash contingent value rights of up to $0.30 per share, to be paid upon reaching specific regulatory and sales milestones. AstraZeneca stated in a Tuesday release that the cash portion of the deal is $1 billion, representing a 62.0% premium over GRCN's last closing price of $6.19 per share. With the additional contingent value, the total value of the deal could reach $1.2 billion.This
Share Xmas Plan and Spread Holiday Fun!
It's the season to share and spread some merry vibes! Whether it's a cozy family gathering, a festive feast, or an adventurous escapade to a winter wonderland, Let's make this holiday season even merrier by swapping tales of cheer! ----------------------- Have you begun your Christmas holiday? What's your plan? Will you spend Xmas with your family or friends?
+ Follow
+15